Nano Smart Pharma collaborates with University of California
Private biotechnology company NanoSmart Pharmaceuticals has signed a research collaboration agreement with University of California to continue the development of NanoSmart’s novel drug delivery platform to treat cancer and other life-threatening diseases.
Dr. James Smith, President of NanoSmart Pharmaceuticals said, “We are very excited to work closely with Dr. Noah Federman and his colleagues at ULCA, as they will provide access to an extraordinary level of research, development and clinical resources.”
Mr. Smith also said, “Their expertise in the development of nanotechnology-based drugs will enable us to continue making efficient progress towards commercializing these products.”
NanoSmart’s patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of tumors. When combined with already FDA-approved drugs, this patented technology allows for the creation of a broad range of next-generation, safer and more effective cancer drug products.
Dr. Noah Federman, Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, a part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center; and Assistant Professor of Pediatrics, Hematology/Oncology at Mattel Children's Hospital at UCLA, said, “Despite the extensive research into new drug formulations, the pace of advancing benefit to this patient population is unfortunately slowing.” He also said, “We are pleased to collaborate with NanoSmart to help drive the development of these much-needed products."
UCLA’s Jonsson Comprehensive Cancer Center is the nation’s largest top-ranked comprehensive cancer research centers.
NanoSmart Pharmaceuticals, Inc is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases. It has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of it lead candidate drug products.
